SUPERIOR REDUCTION OF MAJOR BLEEDING1,*
Once-daily LIXIANA® (edoxaban) was superior to warfarin in reducing the risk of major bleeding events1,*
The primary safety endpoint in the ENGAGE AF-TIMI 48 clinical trial was reduction in risk of major bleeding* events.
The safety of LIXIANA® (edoxaban) was also established in subpopulations of eligible NVAF patients—including those with factors that increase the risk of bleeding.1,2,*
Once-daily LIXIANA® (edoxaban) was also associated with significantly lower rates of intracranial, life-threatening, and fatal bleeding compared with well-managed warfarin1
Once-daily LIXIANA® (edoxaban) significantly reduced the primary net clinical outcome compared with warfarin1
The primary net clinical outcome of stroke, systemic embolic events, major bleeding, and all-cause mortality was reduced by 11% compared with well-managed warfarin (7.26% vs 8.11%, respectively; HR, 0.89; 95% CI, 0.83 to 0.96; P=0.003)1